Assertio Holdings (ASRT) EV/EBITDA Multiple
Assertio Holdings, Inc. (ASRT) is pursuing a strategy of active acquisition and modernization of existing neurological assets to expand its migraine treatment portfolio. This chart illustrates the share value in terms of EV/EBITDA, which is recorded at 31.35. Stable income is generated by legacy drugs with zero depreciation, while strict DEA oversight of opioids creates a defensive barrier for this analgesic drug system.
Analytical breakdowns for Assertio Holdings, Inc.
- market price and analyst price targets:
- market capitalization details:
- issuer book value statistics:
- debt and liquidity data:
- business earnings and investment ratios data:
ASRT - Company Net Income|Expected Profit Assertio Holdings, Inc.|ASRT - Price to Earnings Ratio|Forward P/E Multiple Assertio|ASRT - Growth-Adjusted P/E Ratio|EV/EBITDA Multiple ASRT|ASRT - Operating income before deduction of amortization|Earnings per share for the last twelve months Assertio|ASRT - Earnings per share for the last 12 months|Quarterly EPS earnings growth assertiotx.com|ASRT - Net earnings per share change in current year|Net earnings per share growth forecast for next year Assertio Holdings, Inc.
Initial company analysis:Assertio Therapeutics (ASRT)
The digital promotion model for niche drugs at Assertio Holdings, Inc. (ASRT) requires significant capital expenditures, making the company's EV/EBITDA ratio, adjusted for debt load, a key analytical tool. This metric compares the total enterprise value, including net debt, with operating profit before interest, taxes, depreciation, and amortization, allowing investors to objectively assess the asset's real value without the distortions created by debt leverage.
Key competitors
Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Biogen Corp BIIB|Total Company Value to Operating Income Before Depreciation Ratio Neurocrine Corp (NBIX)|Regencell Bioscience - EV/EBITDA Multiple|Company Value to EBITDA axsome.com|ACADIA Pharmaceuticals Inc. (ACAD) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Xenon Pharmaceuticals Inc. - Business Value to Operating Income Before Depreciation|Enterprise Value to EBITDA Ratio VKTX|SUPN (Supernus Corp) - Enterprise Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple CPRX|Total Company Value to Operating Income Before Depreciation Ratio denalitherapeutics.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Harmony Biosciences Holdings, Inc. HRMY|Biohaven Ltd (BHVN) - Company Value to EBITDA|AMLX: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation TRVI (Trevi Corp)|PRAX: EV/EBITDA Multiple|anavex.com - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization CeriBell|Company Value to EBITDA Prothena Corporation PLC PRTA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Alector, Inc. (ALEC)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization ANNX (Annexon Biosciences Inc.)|EV/EBITDA Multiple OMER (Omeros)|NGNE: Enterprise Value to Operating Income Before Depreciation|AC Immune SA - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio Voyager Therapeutics Inc VYGR|Neumora Therapeutics Inc (NMRA) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation SCLX|TVGN (Tevogen Bio Holdings) - EV/EBITDA Multiple|ACOG - Enterprise Value to EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Cognition Therapeutics, Inc. (CGTX)|Total Company Value to Operating Income Before Depreciation Ratio Inhibikase Therapeutics Inc|Cassava - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation COYA|VistaGen Therapeutics Inc - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio Ovid Therapeutics Inc. OVID|Acumen Pharmaceuticals, Inc. (ABOS) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation CRVO|ATHE (Alterity Therapeutics Ltd.) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Clene Nanomedicine (CLNN)|Enterprise Value to EBITDA Ratio PEPG (PepGen Inc.)|Total Company Value to Operating Income Before Depreciation Ratio jupiterneurosciences.com|EV/EBITDA Multiple RLMD (Relmada Therapeutics, Inc.)|EV/EBITDA Multiple Annovis Bio Inc ANVS|GRCE - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Total Company Value to Operating Income Before Depreciation Ratio Firefly Neuro AIFF|anewmeds.com (KLTO) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|NeuroSense Therapeutics Ltd. - Business Value to Operating Income Before Depreciation|Enterprise Value to EBITDA Ratio RVPH|MTVA (MetaVia, Inc.) - Enterprise Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization NeurAxis, Inc (NRXS)|heliusmedical.com - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple PASG (Passage Bio)|Neuphoria Therapeutics, Inc. (NEUP) - Company Value to EBITDA|NERV: Enterprise Value to EBITDA Ratio|ATHA - EV/EBITDA Multiple|Addex Therapeutics, Ltd. (ADXN) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Alzamend Neuro - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Cyclerion Therapeutics Inc.|Company Value to EBITDA Protagenic PTIX|EV/EBITDA Multiple KTTA|EV/EBITDA Multiple cortigent.com (CRGT)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Avenue Therapeutics, Inc ATXI|Total Company Value to Operating Income Before Depreciation Ratio BrainStorm Cell Therapeutics Inc. (BCLI)|CARA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Total Company Value to Operating Income Before Depreciation Ratio chromocell.com CHRO|ELYM: EV/EBITDA Multiple|Company Value to EBITDA Intra-Cellular Therapies, Inc. (ITCI)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Longboard Pharma|MRNS: Business Value to Operating Income Before Depreciation|Enterprise Value to EBITDA Ratio NKGN (NKGen Biotech, Inc.)|Enterprise Value to Operating Income Before Depreciation Ratio NRBO|EV/EBITDA Multiple SAGE (Sage Therapeutics)|Total Company Value to Operating Income Before Depreciation Ratio Synaptogenix Inc. (SNPX)|TRVN - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Vigil Neuroscience|WENA (Anew Medical, Inc.) - Enterprise Value to EBITDA Ratio|cerevel.com - Business Value to Operating Income Before Depreciation
